Consumer Group Urges Hospitals To Stop Promoting Questionable Screenings
Consumer advocacy group Public Citizen on Thursday called on 20 hospital systems to stop partnering with companies that offer low-cost screenings for heart disease and stroke risk, saying the promotions are “unethical” and the exams are more likely to do harm than good.
Anti-CD20 Antibody Improves Lenalidomide Performance in CLL
From 20 months to upto 5 years, blocking CD20 significantly improved OS in CLL patients.
Need Better Representation of Women and Minorities in Trials: Democrats
Twenty-two Democratic lawmakers have asked the National Institutes of Health to publicly disclose demographic data for all clinical trials posted on
As Sequencing Moves into Clinical Use, Insurers Balk
Once strictly the domain of research labs, gene-sequencing tests increasingly are being used to help understand the genetic causes of rare disease, putting insurance companies in the position of deciding whether to pay the $5,000 to $17,000 for the tests.
ACO Initiatives Test Pharma's Traditional Sales Model
The US healthcare system’s shift from volume- to value-based reimbursement for treatment in order to lower costs and improve patient care is disrupting healthcare business models. The high-profile government–led accountable care organizations (ACOs), which put financial pressure on payers and providers to share responsibility for meeting quality and cost goals, is no exception.
AJMC Sets Infectious Disease Meeting for Atlanta
The American Journal of Managed Care will host a two-day event September 25-26, 2014, to take on some of healthcare’s biggest challenges: Treatments that cure hepatitis C are making news but upending balance sheets. A recent recommendation seeks preventive therapy to stop new cases of HIV. Hospitals and public health officials are grappling with how to prevent the spread of MERS. Only AJMC will bring payers, clinicians, policy leaders, and pharmaceutical representatives together to share ideas.
Alternate Indications: Heparin Derivative in Treating Neuroblastoma?
The derivative slowed tumor growth, shrunk tumors, and extended the life of the mice.
BRCA2 Associated With Risk of Lung Cancer Among Smokers
BRCA2 mutation, a genetic risk factor for breast and ovarian cancer, has been implicated in squamous cell lung cancer among cigarette smokers.
HHS Will Enforce Disputed Rule Limiting Orphan Exclusion from 340B Drug Discounts
HHS is moving forward with its plan to allow certain hospitals to receive discounts on orphan drugs when they are used for non-orphan conditions despite a court ruling that said the agency did not have the authority to do so.
3D Mammograms More Powerful than 2D
In community-based radiology practice, mammography screening with 3D digital breast tomosynthesis (DBT) yielded lower recall rates, an increased overall cancer detection rate, and an increased detection rate for invasive cancer compared with 2D digital mammography (DM).
Insurer Begins Huge Palliative Care Program
“Person-centered care” is the buzz phrase floating around the health care industry, and a Pacific Northwest-based giant insurer thinks it has hit the mark with a new palliative care program coming this summer.
Former ONC Chief Mostashari Heads ACO Startup
Dr. Farzad Mostashari, former head of the Office of the National Coordinator for Health Information Technology, is starting a new firm, Aledade, to help independent primary-care physicians form accountable care organizations.
Pfizer Steps into the CAR-T Immunotherapy Field With Cellectis Deal
Pfizer's deal with the French company will ensure a market share in the promising immunooncology field.
Fast Track Status for the Oncolytic Virus Treatment Being Developed by DNAtrix
The oncolytic adenovirus vaccine, DNX-2401, being developed by DNAtrix to treat recurrent glioblastoma, has received a fast-track status by the FDA.
Personalized Mouse TumorGrafts to Evaluate Treatment Benefits
Icahn School of Medicine at Mount Sinai and Champions Oncology have initiated a study evaluating TumorGrafts' ability to predict treatment benefit in patients with triple-negative breast cancer. A side-by-side genomic analysis of patients' tumor and TumorGraft mouse avatars, before and after treatment, will also be conducted.
Movement Toward Exchanges Faster than Anticipated
Two measures of the evolving health insurance market show that change is happening more quickly than anticipated.
Low-dose Dexamethasone with Pomalidomide Significantly Improves OS in MM
Low-dose dexamethasone with pomalidomide improved overall survival to 12.7 months, compared to 5.7 months with high-dose dexamethasone.
Lung-MAP Study Kicked-off at Multiple Hospitals in the United States
A bold new way to test cancer drugs started Monday in hundreds of hospitals around the United States.
Proteomics to Confirm Treatment Benefit in NSCLC
A proteomic test can predict outcome with chemotherapy versus erlotinib in NSCLC patients.
3 ACO Lessons from Integrated Systems
Integrated healthcare systems, with associated providers and health plans, have a leg up on implementing accountable care organizations to improve care and lower costs. Leaders from two Washington-based integrated systems shared some best practices and lessons learned for ACO success during a panel discussion Thursday at the AHIP Institute in Seattle.
Drugmakers Lash Back at Insurers in War of Words Over Rx Prices
After enduring a rhetorical bashing over the cost of hepatitis C wonder drug Sovaldi, drug manufacturers released a study this week documenting the high cost-sharing rates charged by some insurers on health plans sold through the public exchanges.
Lymphoseek Receives FDA Approval For Diagnosis of HNSCC
The FDA has approved the diagnostic agent technetium 99m tilmanocept for the detection of the spread of head and neck cancers.
Sophisticated Chest Scans in Children: Increased Risk of Heart Disease
Cutting edge technology used to image young children with heart disease increases their risk of cancer.
HHS Fights Back to Keep Expanded 340B Drug Discounts
The drug industry scored a victory last month against the Obama administration's plans to give hospitals millions of dollars in discounts through the 340B program on orphan drugs. But HHS is sticking to its position that the Patient Protection and Affordable Care Act promises breaks on the expensive drugs when they're used for non-orphan indications.